Adam R Craig is President and CEO of CTI BIOPHARMA CORP. Currently has a direct ownership of 0 shares of CTIC, which is worth approximately $0. The most recent transaction as insider was on Jun 26, 2023, when has been sold 31,470 shares (Common Stock) at a price of $9.1 per share, resulting in proceeds of $286,377. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0
0% 3M change
0% 12M change
Total Value Held $0

Adam R Craig Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jun 26 2023
SELL
Disposition due to a tender of shares in a change of control transaction
$286,377 $9.1 p/Share
31,470 Reduced 100.0%
0 Common Stock
Jan 24 2023
SELL
Open market or private sale
$512,755 $6.01 p/Share
85,317 Reduced 74.35%
29,440 Common Stock
Jan 24 2023
BUY
Exercise of conversion of derivative security
$71,666 $0.84 p/Share
85,317 Added 73.0%
31,557 Common Stock
Jan 03 2023
SELL
Open market or private sale
$508,944 $6.01 p/Share
84,683 Reduced 74.2%
29,440 Common Stock
Jan 03 2023
BUY
Exercise of conversion of derivative security
$71,133 $0.84 p/Share
84,683 Added 42.6%
114,123 Common Stock
Dec 30 2022
SELL
Open market or private sale
$102,600 $6.0 p/Share
17,100 Reduced 36.74%
29,440 Common Stock
Dec 30 2022
BUY
Exercise of conversion of derivative security
$14,364 $0.84 p/Share
17,100 Added 33.57%
33,840 Common Stock
Dec 30 2022
BUY
Grant, award, or other acquisition
$8,068 $5.11 p/Share
1,579 Added 5.09%
29,440 Common Stock
Dec 29 2022
SELL
Open market or private sale
$82,800 $6.0 p/Share
13,800 Reduced 33.12%
27,861 Common Stock
Dec 29 2022
BUY
Exercise of conversion of derivative security
$11,592 $0.84 p/Share
13,800 Added 24.88%
41,661 Common Stock
Nov 10 2022
SELL
Open market or private sale
$1,133,590 $6.02 p/Share
188,304 Reduced 87.11%
27,861 Common Stock
Nov 10 2022
BUY
Exercise of conversion of derivative security
$158,175 $0.84 p/Share
188,304 Added 46.56%
216,165 Common Stock
Nov 09 2022
SELL
Open market or private sale
$324,515 $6.01 p/Share
53,996 Reduced 65.96%
27,861 Common Stock
Nov 09 2022
BUY
Exercise of conversion of derivative security
$45,356 $0.84 p/Share
53,996 Added 39.75%
81,857 Common Stock
Sep 12 2022
SELL
Open market or private sale
$1,557,989 $6.43 p/Share
242,300 Reduced 89.69%
27,861 Common Stock
Sep 12 2022
BUY
Exercise of conversion of derivative security
$203,532 $0.84 p/Share
242,300 Added 47.28%
270,161 Common Stock
Aug 16 2022
BUY
Open market or private purchase
$27,500 $5.5 p/Share
5,000 Added 15.22%
27,861 Common Stock
Jul 06 2022
SELL
Open market or private sale
$111,343 $6.11 p/Share
18,223 Reduced 44.36%
22,861 Common Stock
Jul 06 2022
BUY
Exercise of conversion of derivative security
$15,307 $0.84 p/Share
18,223 Added 30.73%
41,084 Common Stock
Jul 05 2022
SELL
Open market or private sale
$162,000 $6.0 p/Share
27,000 Reduced 54.15%
22,861 Common Stock
Jul 05 2022
BUY
Exercise of conversion of derivative security
$22,680 $0.84 p/Share
27,000 Added 35.13%
49,861 Common Stock
Jul 01 2022
SELL
Open market or private sale
$162,000 $6.0 p/Share
27,000 Reduced 54.15%
22,861 Common Stock
Jul 01 2022
BUY
Exercise of conversion of derivative security
$22,680 $0.84 p/Share
27,000 Added 35.13%
49,861 Common Stock
Jun 30 2022
BUY
Grant, award, or other acquisition
$13,108 $2.12 p/Share
6,183 Added 21.29%
22,861 Common Stock
Jun 03 2022
SELL
Open market or private sale
$109,520 $6.01 p/Share
18,223 Reduced 52.21%
16,678 Common Stock
ARC

Adam R Craig

President and CEO
Seattle, WA

Track Institutional and Insider Activities on CTIC

Follow CTI BIOPHARMA CORP and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CTIC shares.

Notify only if

Insider Trading

Get notified when an Cti Biopharma Corp insider buys or sells CTIC shares.

Notify only if

News

Receive news related to CTI BIOPHARMA CORP

Track Activities on CTIC